IUS: Buy The Middle Path In A Narrow, Expensive Market

The article rates Invesco RAFI Strategic US ETF (IUS) a Buy for value-oriented investors, citing a 27.73% top-10 weight and a P/E of 18.83, both lower than SPY's. It says IUS has outperformed VTV and MFUS on risk-adjusted returns since inception, while retaining measured allocations to large-cap leaders including MSFT, NVDA, AMZN, GOOGL, and META.

Analysis

IUS is better understood as a possible reduction in benchmark concentration than as a hedge against a technology-led drawdown: the named mega-cap holdings leave meaningful exposure to the same earnings and sentiment complex driving broad-index returns. The key portfolio question is whether its fundamental weighting and quality screen change the sources of risk enough to justify tracking error—not whether a lower headline P/E guarantees downside protection. That valuation comparison is not decision-grade until the measurement basis, sector mix, and current holdings are verified.

The contrarian risk is factor timing. If AI-related earnings expectations and momentum continue to dominate, a fundamentals-weighted approach may lag as market-cap leaders keep compounding; if leadership broadens or valuation multiples compress, it could benefit from less dependence on the largest winners. Historical risk-adjusted outperformance is not evidence that this regime change is underway, particularly without comparable periods and drawdown data. Near term, the catalyst is relative performance and flows; over 1–3 months, monitor holdings, rebalance effects, and tracking error. Over 6–18 months, the thesis depends on breadth and earnings growth outside the largest growth names.

Key Decisions for Investors

• Treat IUS as a measured diversification allocation, not a defensive substitute for equities. Before adding, verify current sector weights, top holdings, benchmark, fee, and drawdowns against SPY and VTV.
• No high-conviction pair trade on this evidence alone. For an existing SPY-heavy portfolio, consider a staged switch of a small allocation to IUS only if the objective is lower single-name concentration and tracking error is acceptable.
• Watch the next 1–3 months of relative returns and holdings changes. Reassess if IUS continues to lag while market leadership remains narrow; that would weaken the case for reallocating on valuation grounds alone.
• Falsify the diversification thesis if verified holdings show concentration remains driven by the same mega-cap growth exposures, or if a broad selloff produces no meaningful drawdown improvement versus SPY. Do not infer that from the headline P/E comparison without consistent valuation definitions.